Kalaris Therapeutics Inc
KLRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$58.93M
Close$
$6.33
134.3% upside
Current Fair Value
134.3% upsideUndervalued by 134.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $58.93 Million |
|---|---|
| Enterprise Value | $-34,256,674.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.85 |
| Beta | 0.21 |
| Outstanding Shares | 23,797,000 |
Return
| Return on Equity | -76.75% |
|---|---|
| Return on Assets | -44.47% |
| Return on Invested Capital | -52.60% |
Valuation & Multiples
| P/E Ratio | -1.34 |
|---|---|
| PEG | -91.94 |
| Price to Sales | - |
| Price to Book Ratio | 1.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.72 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 75.79%▼ 2.52% |
|---|---|
| Total Invested | $73.41M▼ 31.51% |
| Investors Holding | 56▼ 2.00% |
ESG Score
No data
About Kalaris Therapeutics Inc
14 employees
CEO: Mr. Andrew Oxtoby Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.